High throughput formulation screening for global aggregation behaviors of three monoclonal antibodies

Journal of Pharmaceutical Sciences

Volumn 100, Issue 6, 2011, Pages 2120-2135

  Li, Yi ^a   Mach, Henryk ^a   Blue, Jeffrey T ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Fluorescence spectroscopy; High throughput technologies; Light scattering; Monoclonal antibody; Protein aggregation; Protein formulation; Stability

Indexed keywords

IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; MONOCLONAL ANTIBODY;

ARTICLE; DRUG FORMULATION; FLUORESCENCE SPECTROSCOPY; HIGH THROUGHPUT SCREENING; IONIC STRENGTH; LIGHT SCATTERING; PH; PROTEIN AGGREGATION;

EID: 79954498279     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22450     Document Type: Article

References (40)

1. Capelle MA, Gurny R, Arvinte T. 2007. High throughput screening of protein formulation stability: Practical considerations. Eur J Pharm Biopharm 65(2):131-148.
2. Senisterra GA, Finerty PJ Jr. 2009. High throughput methods of assessing protein stability and aggregation. Mol Biosyst 5(3):217-223.
3. Chi EY, Krishnan S, Randolph TW, Carpenter JF. 2003. Physical stability of proteins in aqueous solution: Mechanism and driving forces in nonnative protein aggregation. Pharm Res 20(9):1325-1336.
4. Roberts CJ. 2006. Non-native protein aggregation: Pathways, kinetics, and shelf-life prediction. In Misbehaving proteins: Protein misfolding, aggregation, and stability; Murphy RM, Tsai AM, Eds. New York: Springer, pp 17-46.
5. Weiss WF IV, Young TM, Roberts CJ. 2009. Principles, approaches, and challenges for predicting protein aggregation rates and shelf life. J Pharm Sci 98(4):1246-1277.
6. Bogard WC Jr, Dean RT, Deo Y, Fuchs R, Mattis JA, McLean AA, Berger HJ. 1989. Practical considerations in the production, purification, and formulation of monoclonal antibodies for immunoscintigraphy and immunotherapy. Semin Nucl Med 19(3):202-220.
7. Shire SJ, Shahrokh Z, Liu J. 2004. Challenges in the development of high protein concentration formulations. J Pharm Sci 93(6):1390-1402.
8. Wang W, Singh S, Zeng DL, King K, Nema S. 2007. Antibody structure, instability, and formulation. J Pharm Sci 96(1):1-26.
9. Daugherty AL, Mrsny RJ. 2006. Formulation and delivery issues for monoclonal antibody therapeutics. Adv Drug Deliv Rev 58(5-6):686-706.
10. Narhi LO, Jiang Y, Cao S, Benedek K, Shnek D. 2009. A critical review of analytical methods for subvisible and visible particles. Curr Pharm Biotechnol 10(4):373-381.
11. Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJ, Middaugh CR, Winter G, Fan YX, Kirshner S, Verthelyi D, Kozlowski S, Clouse KA, Swann PG, Rosenberg A, Cherney B. 2009. Overlooking subvisible particles in therapeutic protein products: Gaps that may compromise product quality. J Pharm Sci 98(4):1201-1205.
12. Li Y, Roberts CJ. 2009. Lumry-Eyring nucleated-polymerization model of protein aggregation kinetics. 2. Competing growth via condensation and chain polymerization. J Phys Chem B 113(19):7020-7032.
13. Chan LL, Lidstone EA, Finch KE, Heeres JT, Hergenrother PJ, Cunningham BT. 2009. A method for identifying small molecule aggregators using photonic crystal biosensor microplates. Conf Proc IEEE Eng Med Biol Soc 2009:788-791.
14. Scotter EL, Narayan P, Glass M, Dragunow M. 2008. High throughput quantification of mutant huntingtin aggregates. J Neurosci Methods 171(1):174-179.
15. Sugiki T, Yoshiura C, Kofuku Y, Ueda T, Shimada I, Takahashi H. 2009. High-throughput screening of optimal solution conditions for structural biological studies by fluorescence correlation spectroscopy. Protein Sci 18(5):1115-1120.
16. Kim W, Kim Y, Min J, Kim DJ, Chang YT, Hecht MH. 2006. A high-throughput screen for compounds that inhibit aggregation of the Alzheimer's peptide. ACS Chem Biol 1(7):461-469.
17. Lee JS, Ryu J, Park CB. 2009. High-throughput analysis of Alzheimer's beta-amyloid aggregation using a microfluidic self-assembly of monomers. Anal Chem 81(7):2751-2759.
18. He F, Hogan S, Latypov RF, Narhi LO, Razinkov VI. 2010. High throughput thermostability screening of monoclonal antibody formulations. J Pharm Sci 99(4):1707-1720.
19. Li Y, Ogunnaike BA, Roberts CJ. 2010. Multi-variate approach to global protein aggregation behavior and kinetics: effects of pH, NaCl, and temperature for alpha-chymotrypsinogen A. J Pharm Sci 99(2):645-662.
20. Sahin E, Grillo AO, Perkins MD, Roberts CJ. Comparative effects of pH and ionic strength on protein-protein interactions, unfolding, and aggregation for IgG1 antibodies. J Pharm Sci. 99(12):4830-4848.
21. Andrews JM, Roberts CJ. 2007. A Lumry-Eyring nucleated polymerization model of protein aggregation kinetics: 1. Aggregation with pre-equilibrated unfolding. J Phys Chem B 111(27):7897-7913.
22. Pallitto MM, Murphy RM. 2001. A mathematical model of the kinetics of beta-amyloid fibril growth from the denatured state. Biophys J 81(3):1805-1822.
23. Li Y, Weiss WF IV, Roberts CJ. 2009. Characterization of high-molecular-weight nonnative aggregates and aggregation kinetics by size exclusion chromatography with inline multi-angle laser light scattering. J Pharm Sci.98(11):3997-4016
24. Li Y. 2009. Global non-native aggregation behavior for alpha-chymotrypsinogen A. Ph.D. Thesis. Delaware: Department of Chemical Engineering, University of Delaware, pp 271.
25. Carrotta R, Bauer R, Waninge R, Rischel C. 2001. Conformational characterization of oligomeric intermediates and aggregates in beta-lactoglobulin heat aggregation. Protein Sci 10(7):1312-1318.
26. Chiti F, Taddei N, Baroni F, Capanni C, Stefani M, Ramponi G, Dobson CM. 2002. Kinetic partitioning of protein folding and aggregation. Nat Struct Biol 9(2):137-143.
27. Fink AL. 1998. Protein aggregation: Folding aggregates, inclusion bodies and amyloid. Fold Des 3(1):R9-R23.
28. Mahler HC, Friess W, Grauschopf U, Kiese S. 2008. Protein aggregation: Pathways, induction factors and analysis. J Pharm Sci. 98(9):2909-2934.
29. Roberts CJ. 2007. Non-native protein aggregation kinetics. Biotechnol Bioeng 98(5):927-938.
30. Chiti F, Stefani M, Taddei N, Ramponi G, Dobson CM. 2003. Rationalization of the effects of mutations on peptide and protein aggregation rates. Nature 424(6950):805-808.
31. Niesen FH, Berglund H, Vedadi M. 2007. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat Protoc 2(9):2212-2221.
32. Demeule B, Gurny R, Arvinte T. 2007. Detection and characterization of protein aggregates by fluorescence microscopy. Int J Pharm 329(1-2):37-45.
33. Hawe A, Sutter M, Jiskoot W. 2008. Extrinsic fluorescent dyes as tools for protein characterization. Pharm Res 25(7):1487-1499.
34. Munishkina LA, Fink AL. 2007. Fluorescence as a method to reveal structures and membrane-interactions of amyloidogenic proteins. Biochim Biophys Acta 1768(8):1862-1885.
35. Andrews JM, Roberts CJ. 2007. Non-native aggregation of alpha-chymotrypsinogen occurs through nucleation and growth with competing nucleus sizes and negative activation energies. Biochemistry 46(25):7558-7571.
36. LeVine H 3rd. 1997. Stopped-flow kinetics reveal multiple phases of thioflavin T binding to Alzheimer beta (1-40) amyloid fibrils. Arch Biochem Biophys 342(2):306-316.
37. Nielsen L, Khurana R, Coats A, Frokjaer S, Brange J, Vyas S, Uversky VN, Fink AL. 2001. Effect of environmental factors on the kinetics of insulin fibril formation: Elucidation of the molecular mechanism. Biochemistry 40(20):6036-6046.
38. Lindgren M, Sorgjerd K, Hammarstrom P. 2005. Detection and characterization of aggregates, prefibrillar amyloidogenic oligomers, and protofibrils using fluorescence spectroscopy. Biophys J 88(6):4200-4212.
39. Arakawa T, Timasheff SN. 1985. Theory of protein solubility. Methods Enzymol 114:49-77.
40. Bee JS, Chiu D, Sawicki S, Stevenson JL, Chatterjee K, Freund E, Carpenter JF, Randolph TW. 2009. Monoclonal antibody interactions with micro- and nanoparticles: Adsorption, aggregation, and accelerated stress studies. J Pharm Sci 98(9):3218-3238.